JPRN-jRCT2080223674已完成3 期
A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •History of cytologically or histologically confirmed diagnosis of AML (except acute promyelocytic leukemia) according to the 2008 World Health Organization (WHO) classification (bone marrow [BM] or peripheral blood [PB] blast counts 20% or more).
- •-Performance status (Eastern Cooperative Oncology Group; ECOG) of 0-2.
- •-Subjects with AML previously treated with initial induction therapy using a standard intensive chemotherapy regimen, including cytarabine and an anthracycline, and who are refractory to initial induction (primary refractory) or in relapse after such initial induction.
- •-Subjects must have either PB or BM blasts 5% or more at time of randomization.
- •-Creatinine clearance or glomerular filtration rate 30 mL/min or more as estimated by the Cockroft-Gault (C-G) or other medically acceptable formulas, such as MDRD (Modification of Diet in Renal Disease) or CKD-EPI (the Chronic Kidney Disease Epidemiology Collaboration).
- •-Women of child-bearing potential must not be pregnant or breastfeeding and must have a negative pregnancy test at screening. Women of child-bearing potential and men with female partners of child-bearing potential must agree to practice 2 highly effective contraceptive measures of birth control and must agree not to become pregnant or father a child while receiving any study therapy and for at least 3 months after completing treatment.
排除标准
- •-Known clinically active central nervous system (CNS) or extramedullary AML, except leukemia cutis.
- •-Subjects in first relapse after initial induction who had a response duration more than 12 months OR favorable cytogenetics since those subjects may benefit from re-induction with the same or similar prior regimen.
- •-BCR-ABL-positive leukemia (chronic myelogenous leukemia in blast crisis).
- •-Second malignancy currently requiring active therapy, except breast or prostate cancer stable on or responding to endocrine therapy.
- •-Grade 3 or higher Graft Versus Host Disease (GVHD), or GVHD on either a calcineurin inhibitor or prednisone more than 5 mg/day.
- •-Prior treatment with decitabine, azacitidine, or guadecitabine.
- •-Hypersensitivity to decitabine, guadecitabine, or any of their excipients.
- •-Treated with any investigational therapy within 2 weeks of the first dose of study treatment.
- •-Total serum bilirubin more than 2.5 * upper limit of normal (ULN; except for subjects with Gilbert's Syndrome for whom direct bilirubin is less than 2.5 * ULN), or liver cirrhosis, or chronic liver disease Child-Pugh Class B or C.
- •-Known active human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection. Inactive hepatitis carrier status or low viral hepatitis titer on antivirals is allowed.
- •-Known significant mental illness or other condition such as active alcohol or other substance abuse or addiction that, in the opinion of the investigator, predisposes the subject to high risk of noncompliance with the protocol.
- •-Refractory congestive heart failure unresponsive to medical treatment; active infection resistant to all antibiotics; or non-AML-associated pulmonary disease requiring more than 2 liters per minute (LPM) oxygen.
研究者
相似试验
进行中（未招募）
1 期
A Phase 3 Study to Compare Avelumab Given Alone or Given in Combination with Pegylated Liposomal Doxorubicin Compared to Pegylated Liposomal Doxorubicin Given Alone Patients with Platinum-Resistant/Refractory Ovarian CancerOvarian CancerMedDRA version: 20.0 Level: PT Classification code 10033128 Term: Ovarian cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-003091-77-PLPfizer Inc., 235 East 42nd Street, New York, NY 10017550
进行中（未招募）
1 期
A clinical trial to assess and compare overall survival (OS) between guadecitabine and treatment choice (TC) in adults with previously treated acute myeloid leukemia (AML)Acute Myeloid Leukemia (AML)MedDRA version: 20.0Level: HLTClassification code 10024291Term: Leukaemias acute myeloidSystem Organ Class: 100000004851EUCTR2015-005256-97-BEAstex Pharmaceuticals, Inc.300
进行中（未招募）
1 期
A Phase 3 Study to Compare Avelumab Given Alone or Given in Combination with Pegylated Liposomal Doxorubicin Compared to Pegylated Liposomal Doxorubicin Given Alone Patients with Platinum-Resistant/Refractory Ovarian CancerOvarian CancerEUCTR2015-003091-77-NLPfizer Inc., 235 East 42nd Street, New York, NY 10017550
进行中（未招募）
1 期
A clinical trial to compare guadecitabine (SGI-110) to other available therapies in patients with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) who have previously been treated with hypomethylating agentsEUCTR2015-005257-12-DKAstex Pharmaceuticals, Inc.408
进行中（未招募）
1 期
A Phase 3 Study to Compare Avelumab Given Alone or Given in Combination with Pegylated Liposomal Doxorubicin Compared to Pegylated Liposomal Doxorubicin Given Alone Patients with Platinum-Resistant/Refractory Ovarian CancerOvarian CancerEUCTR2015-003091-77-FRPfizer Inc, 235 East 42nd Street, New York, NY 10017550